bright ideas
made brilliant

We take current therapies and make them better.

at Propella

We advance promising therapies with high efficiency and reduced risk due to the fact that all of our product candidates are developed using proven active ingredients. Our new and patented best-in-class products appeal to both patients and physicians.

Every day we are earnestly pushing ahead.

our approach

We start with good, and rapidly and intelligently move to great.
> learn more

our pipeline

Discover the potential that is currently underway at Propella
> learn more

latest news

Propella Therapeutics, Inc. presented "A Phase 1/2a, Open-label, Multicenter Study of Intramuscular Abiraterone Decanoate (PRL-02) Depot in Patients with Advanced Prostate Cancer (NCT04729114)" at the American Society of Clinical Oncology Annual Meeting on June 4, 2021.

Propella Therapeutics, Inc., a biopharmaceutical company focused on developing innovative, best-in-class oncology drugs, announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PRL-02 (abiraterone decanoate), a potentially best-in-class therapy for metastatic prostate cancer. Propella also announced the appointment of Brendan Griffin to its leadership team as Chief Financial Officer.

Propella Therapeutics, Inc. (Propella Therapeutics), a leader in the development of innovative, best-in-class prescription products, and the National Cancer Institute (NCI), announced they have entered into a Cooperative Research and Development Agreement (CRADA). Under this new partnership, Propella Therapeutics and NCI will conduct a multi-center clinical trial to evaluate abiraterone decanoate, as a new therapy for metastatic prostate cancer.

“Propella” comes from the combination of “propel”, to drive, push and cause forward or upward motion, and “Capella”, a first magnitude star used in navigation. Capella consists of a primary pair of stars, which enhance, illuminate and strengthen each other, ultimately appearing as one.